Baseline characteristics of the two cohorts of phase 1 and phase 2 patients
| Phase 1 (n=136) | Phase 2 (n=105) | P value | |
| Demographics | |||
| Age, y (median, IQR) | 68; 48–88 | 69; 57–91 | 0.114 |
| Male, sex | 52 (38.2%) | 52 (49.5%) | 0.005 |
| Medical history | |||
| Hypertension | 66 (48.5%) | 61 (58.1%) | 0.067 |
| Diabetes mellitus | 23 (16.9%) | 17 (16.19%) | 0.355 |
| Hypercholesterolaemia | 34 (25%) | 30 (28.6%) | 0.208 |
| Coronary artery disease | 17 (12.5%) | 7 (6.7%) | 0.068 |
| Smoking | 56 (41.2%) | 50 (47.61%) | 0.070 |
| Previous TIA/stroke | 21 (15.4%) | 9 (12.9%) | 0.296 |
| Carotid stenosis | 15 (11%) | 17 (16.2%) | 0.111 |
| Peripheral vascular diseases | 19 (13.97%) | 15 (14.3%) | 0.345 |
| CHAD2DS2-VASc score (median, IQR) | 2; 1–6 | 2; 1–6 | 0.456 |
| Cardiac monitoring | |||
| Duration of the cardiac monitoring (hours) (median, IQR) | 23; 22–24 | 22; 14–30 | 0.541 |
| Time to initiate the cardiac monitoring (days) (median, IQR) | 62; 13–111 | 1; 1–21 | <0.001 |
TIA, transient ischaemic attack.